Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies

Multiple Cancer Types

This is the first study to test Sym013 (Pan-HER) in humans. The primary purpose of this study is to see if Sym013 is safe and effective for patients with advanced epithelial malignancies without available therapeutic options.
Miscellaneous, Phase I
I/II
Berlin, Jordan
NCT02906670
VICCPHI1682

Corticosteroids with or without Bevacizumab in Improving Symptoms in Patients with Radionecrosis after Radiation Surgery for Brain Metastasis

Neuro-Oncology

This randomized phase II trial studies how well corticosteroids and bevacizumab work compared to corticosteroids alone in improving symptoms in patients with radionecrosis after radiation surgery for cancer that has spread from the original tumor to the brain. Brain radionecrosis is a non-cancerous condition in which an area of dead tissue in the brain, caused by treatment with radiation therapy, is surrounded by inflamed (swollen) tissue. Brain radionecrosis can cause headaches, nausea, vomiting, weakness and other neurological symptoms. Corticosteroids, drugs given to reduce inflammation, or swelling, are the most common treatment for brain radionecrosis. Bevacizumab may help reduce inflammation and lessen the symptoms of radionecrosis by reducing leaking of the blood vessels. It is not yet known whether giving corticosteroids alone or with bevacizumab is more effective in treating radionecrosis in patients with brain metastasis.
Neuro-Oncology
II
Attia, Albert
NCT02490878
ECOGNEUA221208

Afatinib and Necitumumab in Treating Patients with EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Multiple Cancer Types

This phase I trial studies the side effects and best dose of afatinib and necitumumab and to see how well they work in treating patients with EGFR mutation positive non-small cell lung cancer that has spread to other places in the body. Afatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as necitumumab, may interfere with the ability of tumor cells to grow and spread. Giving afatinib and necitumumab may work better in treating patients with EGFR mutation positive non-small cell lung cancer.
Lung, Non Small Cell
I
Horn, Leora
NCT03054038
VICCTHO1684

An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

Neuro-Oncology

The purpose of this study is to evaluate patients with glioblastoma that is MGMT-methylated (the MGMT gene is altered by a chemical change). Patients will receive temozolomide plus radiation therapy. They will be compared to patients receiving Nivolumab in addition to temozolomide plus radiation therapy.
Neuro-Oncology
III
Clark, Stephen
NCT02667587
VICCNEU1688

Nintedanib, Idarubicin Hydrochloride, and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia

Leukemia

This phase I / II trial studies the side effects of nintedanib, idarubicin hydrochloride, and cytarabine and to see how well they work in treating patients with acute myeloid leukemia that has come back or does not respond to treatment. Nintedanib may stop the growth of tumor cells by blocking the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as idarubicin hydrochloride and cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nintedanib, idarubicin hydrochloride, and cytarabine may work better in treating patients with acute myeloid leukemia.
Leukemia
I/II
Strickland, Stephen
NCT02665143
VICCHEM1689

Tepotinib Phase II in NSCLC Harbouring MET Exon 14 (METex14) Skipping Alterations

Lung

This study will look at how effective the study drug (tepotinib) is at stopping the growth and spread of lung cancer. This study will also measure a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a particular drug.
Lung
II
Horn, Leora
NCT02864992
VICCTHO1691

Immune Monitoring During ASP2215 Therapy in Relapsed/Refractory Acute Myeloid Leukemia (AML)

Leukemia

Leukemia
N/A
Strickland, Stephen
VICCHEM1697

Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients

Liver

This study is to compare the efficacy and safety of defibrotide prophylaxis in addition to best supportive care versus best supportive care alone in the prevention of hepatic veno- occlusive disease (VOD) in adult and pediatric patients undergoing hematopoietic stem cell transplant who are at high risk or very high risk of developing VOD.
Liver
III
Kitko, Carrie
NCT02851407
VICCPED1698

Plasma Tumor DNA and Pathologic Complete Response in Early-Stage, High-Risk Breast Cancer

Breast

Breast
N/A
Rexer, Brent
NCT02743910
VICCBRE1696

My Pathway: A Study Evaluating Herceptin / Perjeta, Tarceva, Zelboraf / Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Miscellaneous

This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and / or are not suitable options per the treating physician's judgment.
Miscellaneous
II
Davis, Elizabeth
NCT02091141
VICCMD16103

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: